Human methylome studies SRP058102 Track Settings
 
Analysis of DNA Methylation in replication and cell cycle arrest. [Primary Dermal Fibroblasts]

Track collection: Human methylome studies

+  All tracks in this collection (438)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       HMR       PMD       CpG methylation ▾      
Select subtracks by views and experiment:
 All views AMR  CpG reads  HMR  PMD  CpG methylation 
experiment
SRX1021638 
SRX1021639 
SRX1021640 
SRX1021641 
SRX1021642 
SRX1021643 
SRX1021644 
SRX1021645 
SRX1021646 
SRX1021647 
SRX1021648 
SRX1021649 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX1021638  CpG methylation  Primary Dermal Fibroblasts / SRX1021638 (CpG methylation)   Data format 
hide
 SRX1021639  HMR  Primary Dermal Fibroblasts / SRX1021639 (HMR)   Data format 
hide
 Configure
 SRX1021639  CpG methylation  Primary Dermal Fibroblasts / SRX1021639 (CpG methylation)   Data format 
hide
 Configure
 SRX1021640  CpG methylation  Primary Dermal Fibroblasts / SRX1021640 (CpG methylation)   Data format 
hide
 Configure
 SRX1021641  CpG methylation  Primary Dermal Fibroblasts / SRX1021641 (CpG methylation)   Data format 
hide
 SRX1021642  HMR  Primary Dermal Fibroblasts / SRX1021642 (HMR)   Data format 
hide
 Configure
 SRX1021642  CpG methylation  Primary Dermal Fibroblasts / SRX1021642 (CpG methylation)   Data format 
hide
 SRX1021643  HMR  Primary Dermal Fibroblasts / SRX1021643 (HMR)   Data format 
hide
 Configure
 SRX1021643  CpG methylation  Primary Dermal Fibroblasts / SRX1021643 (CpG methylation)   Data format 
hide
 SRX1021644  HMR  Primary Dermal Fibroblasts / SRX1021644 (HMR)   Data format 
hide
 Configure
 SRX1021644  CpG methylation  Primary Dermal Fibroblasts / SRX1021644 (CpG methylation)   Data format 
hide
 SRX1021645  HMR  Primary Dermal Fibroblasts / SRX1021645 (HMR)   Data format 
hide
 Configure
 SRX1021645  CpG methylation  Primary Dermal Fibroblasts / SRX1021645 (CpG methylation)   Data format 
hide
 SRX1021646  HMR  Primary Dermal Fibroblasts / SRX1021646 (HMR)   Data format 
hide
 Configure
 SRX1021646  CpG methylation  Primary Dermal Fibroblasts / SRX1021646 (CpG methylation)   Data format 
hide
 SRX1021647  HMR  Primary Dermal Fibroblasts / SRX1021647 (HMR)   Data format 
hide
 Configure
 SRX1021647  CpG methylation  Primary Dermal Fibroblasts / SRX1021647 (CpG methylation)   Data format 
hide
 SRX1021648  HMR  Primary Dermal Fibroblasts / SRX1021648 (HMR)   Data format 
hide
 Configure
 SRX1021648  CpG methylation  Primary Dermal Fibroblasts / SRX1021648 (CpG methylation)   Data format 
hide
 SRX1021649  HMR  Primary Dermal Fibroblasts / SRX1021649 (HMR)   Data format 
hide
 Configure
 SRX1021649  CpG methylation  Primary Dermal Fibroblasts / SRX1021649 (CpG methylation)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: Analysis of DNA Methylation in replication and cell cycle arrest.
SRA: SRP058102
GEO: GSE68657
Pubmed: 26648411

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX1021638 Primary Dermal Fibroblasts 0.631 8.8 68576 4024.4 90 1298.9 1765 559967.6 0.996 GSM1678122: bisfulfite treated genomic DNA from arrested, G0 fibroblasts A; Homo sapiens; Bisulfite-Seq
SRX1021639 Primary Dermal Fibroblasts 0.636 10.4 67166 3375.8 130 1190.1 2164 450894.9 0.996 GSM1678123: bisfulfite treated genomic DNA from G0 fibroblasts A; Homo sapiens; Bisulfite-Seq
SRX1021640 Primary Dermal Fibroblasts 0.626 6.4 59466 4885.2 25 1307.2 1707 594500.0 0.996 GSM1678124: bisfulfite treated genomic DNA from G1 fibroblasts A; Homo sapiens; Bisulfite-Seq
SRX1021641 Primary Dermal Fibroblasts 0.623 7.6 64095 4602.9 60 1272.6 1674 609056.9 0.996 GSM1678125: bisfulfite treated genomic DNA from G2 fibroblasts A; Homo sapiens; Bisulfite-Seq
SRX1021642 Primary Dermal Fibroblasts 0.623 7.6 56951 3642.9 62 1364.6 1479 749782.5 0.996 GSM1678126: bisfulfite treated genomic DNA from arrested, G0 fibroblasts B; Homo sapiens; Bisulfite-Seq
SRX1021643 Primary Dermal Fibroblasts 0.620 8.3 54904 2986.1 76 1337.1 1441 764062.9 0.996 GSM1678127: bisfulfite treated genomic DNA from G0 fibroblasts B; Homo sapiens; Bisulfite-Seq
SRX1021644 Primary Dermal Fibroblasts 0.626 6.9 53583 3638.6 57 1186.8 1392 791478.5 0.996 GSM1678128: bisfulfite treated genomic DNA from G1 fibroblasts B; Homo sapiens; Bisulfite-Seq
SRX1021645 Primary Dermal Fibroblasts 0.619 6.9 53834 3918.4 80 1106.6 1408 789268.7 0.996 GSM1678129: bisfulfite treated genomic DNA from G2 fibroblasts B; Homo sapiens; Bisulfite-Seq
SRX1021646 Primary Dermal Fibroblasts 0.637 7.8 54064 2496.1 77 1379.1 1406 766420.9 0.996 GSM1678130: bisfulfite treated genomic DNA from arrested, G0 fibroblasts C; Homo sapiens; Bisulfite-Seq
SRX1021647 Primary Dermal Fibroblasts 0.640 8.8 54696 1955.8 96 1211.3 1384 782621.3 0.996 GSM1678131: bisfulfite treated genomic DNA from G0 fibroblasts C; Homo sapiens; Bisulfite-Seq
SRX1021648 Primary Dermal Fibroblasts 0.637 8.9 56204 2227.5 114 1257.9 1413 777228.7 0.996 GSM1678132: bisfulfite treated genomic DNA from G1 fibroblasts C; Homo sapiens; Bisulfite-Seq
SRX1021649 Primary Dermal Fibroblasts 0.629 8.6 56249 2562.1 83 1267.8 1390 799340.2 0.996 GSM1678133: bisfulfite treated genomic DNA from G2 fibroblasts C; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.